"Radioligand Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
| Descriptor ID |
D011869
|
| MeSH Number(s) |
E01.370.225.985 E01.370.374.650 E01.370.384.720 E05.200.985
|
| Concept/Terms |
Radioligand Assay- Radioligand Assay
- Assay, Radioligand
- Assays, Radioligand
- Radioligand Assays
- Radioreceptor Assay
- Assay, Radioreceptor
- Assays, Radioreceptor
- Radioreceptor Assays
- Protein-Binding Radioassay
- Protein Binding Radioassay
- Protein-Binding Radioassays
- Radioassay, Protein-Binding
- Radioassays, Protein-Binding
|
Below are MeSH descriptors whose meaning is more general than "Radioligand Assay".
Below are MeSH descriptors whose meaning is more specific than "Radioligand Assay".
This graph shows the total number of publications written about "Radioligand Assay" by people in this website by year, and whether "Radioligand Assay" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 9 | 9 |
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radioligand Assay" by people in Profiles.
-
Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists. Molecules. 2018 Oct 13; 23(10).
-
Lack of renoprotective effect of chronic intravenous angiotensin-(1-7) or angiotensin-(2-10) in a rat model of focal segmental glomerulosclerosis. PLoS One. 2014; 9(10):e110083.
-
Acute repeated intracerebroventricular injections of angiotensin II reduce agonist and antagonist radioligand binding in the paraventricular nucleus of the hypothalamus and median preoptic nucleus in the rat brain. Brain Res. 2014 Oct 02; 1583:132-40.
-
Functional and structural interaction of (-)-reboxetine with the human a4?2 nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 2013 Jan; 344(1):113-23.
-
Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. J Med Chem. 2010 Jun 24; 53(12):4623-32.
-
Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am. 2010 Jun; 39(2):271-86, table of contents.
-
Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr. 2008 Aug; 88(2):507S-510S.
-
COX-2 expression stimulated by Angiotensin II depends upon AT1 receptor internalization in vascular smooth muscle cells. Biochim Biophys Acta. 2008 Jun; 1783(6):1048-54.
-
Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. J Rheumatol. 2007 Apr; 34(4):734-9.
-
Evaluation of [11C]hemicholinium-15 and [18F]hemicholinium-15 as new potential PET tracers for the high-affinity choline uptake system in the heart. Bioorg Med Chem. 2007 Feb 01; 15(3):1289-97.